ID: ALA2153439

Max Phase: Preclinical

Molecular Formula: C26H25N3O

Molecular Weight: 395.51

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1cccc(-c2ccc(CNC(=O)CCCc3ccc4cccnc4n3)cc2)c1

Standard InChI:  InChI=1S/C26H25N3O/c1-19-5-2-6-23(17-19)21-12-10-20(11-13-21)18-28-25(30)9-3-8-24-15-14-22-7-4-16-27-26(22)29-24/h2,4-7,10-17H,3,8-9,18H2,1H3,(H,28,30)

Standard InChI Key:  PPGSCVIDQKFZTG-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 395.51

Molecular Weight (Monoisotopic): 395.1998

AlogP: 5.24

#Rotatable Bonds: 7

Polar Surface Area: 54.88

Molecular Species: NEUTRAL

HBA: 3

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 0.53

CX LogP: 4.94

CX LogD: 4.94

Aromatic Rings: 4

Heavy Atoms: 30

QED Weighted: 0.47

Np Likeness Score: -1.03

References

1. Bhuniya D, Umrani D, Dave B, Salunke D, Kukreja G, Gundu J, Naykodi M, Shaikh NS, Shitole P, Kurhade S, De S, Majumdar S, Reddy SB, Tambe S, Shejul Y, Chugh A, Palle VP, Mookhtiar KA, Cully D, Vacca J, Chakravarty PK, Nargund RP, Wright SD, Graziano MP, Singh SB, Roy S, Cai TQ..  (2011)  Discovery of a potent and selective small molecule hGPR91 antagonist.,  21  (12): [PMID:21571530] [10.1016/j.bmcl.2011.04.091]

2. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

Source

Source(2):

• Scientific Literature
• AstraZeneca Deposited Data